NCT06102707View on ClinicalTrials.gov

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2026

Conditions

Ovarian Cancer Recurrent

Interventions

DRUG

Fluzopril Combined With Apatinib

Fluzopril Capsules 100mg po bid Apatinib Mesylate Tablets 250mg po qd

All Listed Sponsors

lead

Qilu Hospital of Shandong University

OTHER

NCT06102707 - The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients | Biotech Hunter | Biotech Hunter